Candel Therapeutics appoints Martine Zimmermann to board; BLA submission planned Q4 2026

Candel Therapeutics, Inc.

Board expanded from 10 to 11 directors; Zimmermann appointed effective Sept 8, 2026, as Class III director with term to 2027 annual meeting.
Compensation: option for 64,000 shares vesting monthly over 3 years; $40,000 annual retainer paid quarterly.
Zimmermann brings 30+ years regulatory/quality experience; currently EVP at Inventiva, previously SVP at Ipsen and Alexion.
Company reiterates planned BLA submission for aglatimagene besadenovec in Q4 2026; appointment supports commercial readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.